Genetics, Psychedelics & Epigenetic Reprogramming | Longevity News Roundup — Week 6, 2026

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity, from new insights into genetic influence on lifespan to reproductive longevity, exosome therapeutics, AI health platforms, epigenetic reprogramming, and psychedelics for cognitive resilience.New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.______________________News & References:Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠